Screener
Cytek Biosciences, Inc. CTKB Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income (expense), net | (243) | 3,849 | 847 | 7,557 |
| Loss before income taxes | (11,643) | (6,775) | (29,016) | (18,041) |
| Provision for (benefit from) income taxes | 515 | (1,192) | 2,008 | (1,056) |
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss, basic and diluted | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss per share, basic and diluted | $(0.09) | $(0.04) | $(0.24) | $(0.13) |
| Weighted-average shares used in calculating net loss per share, basic and diluted | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 |
| Comprehensive loss: |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s business segments — net loss?
- Cytek Biosciences, Inc. (CTKB) reported business segments — net loss of -$12.16M in Q2 2026.
- How has Cytek Biosciences, Inc.'s business segments — net loss changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — net loss decreased by 117.8% year-over-year, from -$5.58M to -$12.16M.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — net loss?
- Over 2 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — net loss has grown at a 417.6% compound annual growth rate (CAGR), from $2.48M to -$66.54M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result for the segment when total expenses exceed total revenues. This metric highlights the current profitability status and the extent to which the segment requires external funding or operational adjustments to reach break-even.
Ask your AI about Cytek Biosciences, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude